Minimally invasive techniques for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: An update

Abstract

Benign prostatic hyperplasia (BPH) primarily affects middle-aged and elderly men. Consequently, medical and surgical treatments for this condition are some of the most common therapies administered in medical practice. Many minimally invasive techniques for the treatment of BPH have been introduced over the past several years to achieve comparable efficacy without the morbidity and mortality associated with transurethral resection of the prostate (TURP), the current gold standard for the surgical management of BPH. Many procedures have not sustained satisfactory results over time, whereas others have been reported as possible alternatives, in selected cases, to TURP. It may not be a simple question of comparative efficacy with TURP for these less invasive treatments, but rather a question of whether lower complication and side-effect rates are a suitable tradeoff for somewhat reduced symptom relief and possibly a need for future retreatment. This article reviews current minimally invasive therapies, addressing methods of tissue ablation, short-and long-term results, and comparisons with TURP.

Prospective, Randomized, Double-Blind, Vehicle Controlled, Multicenter Phase IIb Clinical Trial of the Pore Forming Protein PRX302 for Targeted Treatment of Symptomatic Benign Prostatic Hyperplasia

“…Surgical approaches are associated with significant morbidity, including perioperative complications, urinary incontinence, bleeding requiring transfusions and sexual side effects, and re-treatment may be required within 3 years. 10,12 …”